XOMA u picking up this news yet? (COMTEX) B: Xoma wins $1.7 million subcontract from SRI International ( Da tamonitor ) B: Xoma wins $1.7 million subcontract from SRI International ( Datamonitor )
Jul 31, 2009 (Datamonitor via COMTEX) -- Xoma, a biopharmaceutical company, has received a new $1.7 million subcontract from SRI International to produce novel antibody drugs against the virus that causes severe acute respiratory syndrome or SARS, a highly contagious infectious disease that often progresses to pneumonia and may be fatal.
The project is funded under a 2006 prime contract between SRI, a nonprofit scientific research institute based in Menlo Park, California and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Xoma's responsibilities will include the evaluation of several antibodies for growth, productivity, manufacturability and performance in bioreactors. Xoma may receive additional awards under this five year contract.
Previously, NIAID has awarded three contracts for a total of nearly $100 million to Xoma to develop anti-botulism antibodies. The first product candidate resulting from this work, XOMA 3AB, is currently undergoing pre-investigational new drug studies studies.
Steven Engle, chairman and CEO of Xoma, said: "We are pleased that Xoma has been selected for this important new project. Currently, the federal government is funding another key project under which we will develop and evaluate antibody products to the botulinum neurotoxin, with the goal of entering into a long-term manufacturing and stockpiling contract." http://www.datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon Copyright (C) 2009 Datamonitor. All rights reserved *** end of story ***
News 
Market Data 
Discover 
AI
